Drug Profile


Alternative Names: INGREZZA; MT 5199; NBI-98854; Valbenazine-tosylate; VMAT2 inhibitor - Neurocrine Biosciences

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Neurocrine Biosciences
  • Developer Mitsubishi Tanabe Pharma Corporation; Neurocrine Biosciences
  • Class 3-ring heterocyclic compounds; Amino acids; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Drug-induced dyskinesia
  • Phase II Gilles de la Tourette's syndrome
  • Discontinued Huntington's disease; Schizophrenia

Most Recent Events

  • 07 Jun 2017 Mitsubishi Tanabe Pharma Corporation plans a phase II/III trial for Drug-induced dyskinesia in Japan (NCT03176771)
  • 10 May 2017 Neurocrine Biosciences plans pivotal phase III trials for Gilles de la Tourette's syndrome
  • 22 Apr 2017 Adverse events data from a pooled analysis of phase II and III KINECT, KINECT 3 and KINECT 4 trials in Tardive dyskinesia presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top